CN115666629A - 面部皱纹的高剂量和低体积肉毒毒素治疗 - Google Patents

面部皱纹的高剂量和低体积肉毒毒素治疗 Download PDF

Info

Publication number
CN115666629A
CN115666629A CN202180037805.1A CN202180037805A CN115666629A CN 115666629 A CN115666629 A CN 115666629A CN 202180037805 A CN202180037805 A CN 202180037805A CN 115666629 A CN115666629 A CN 115666629A
Authority
CN
China
Prior art keywords
botulinum toxin
lines
dose
days
injected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037805.1A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊娜·罗尔
迈克·斯拉德克
托林·盖斯特
伊连娜·普尔特
佩特拉·维森贝格
古德伦·克莱因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115666629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of CN115666629A publication Critical patent/CN115666629A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202180037805.1A 2020-06-05 2021-06-04 面部皱纹的高剂量和低体积肉毒毒素治疗 Pending CN115666629A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178574 2020-06-05
EP20178574.8 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (1)

Publication Number Publication Date
CN115666629A true CN115666629A (zh) 2023-01-31

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037805.1A Pending CN115666629A (zh) 2020-06-05 2021-06-04 面部皱纹的高剂量和低体积肉毒毒素治疗

Country Status (13)

Country Link
US (2) US12599550B2 (cg-RX-API-DMAC7.html)
EP (2) EP4161562B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023529095A (cg-RX-API-DMAC7.html)
KR (1) KR20230020961A (cg-RX-API-DMAC7.html)
CN (1) CN115666629A (cg-RX-API-DMAC7.html)
AU (1) AU2021286196A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023413A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177835A1 (cg-RX-API-DMAC7.html)
ES (1) ES3013130T3 (cg-RX-API-DMAC7.html)
IL (1) IL298399A (cg-RX-API-DMAC7.html)
MX (1) MX2022014564A (cg-RX-API-DMAC7.html)
TW (1) TW202214211A (cg-RX-API-DMAC7.html)
WO (1) WO2021245223A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186016A1 (zh) * 2022-04-01 2023-10-05 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物、制备方法及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR20250113431A (ko) * 2022-11-28 2025-07-25 메르츠 파마 게엠베하 운트 코. 카가아 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018931A1 (en) * 2004-07-26 2006-01-26 Taylor Harold V Therapeutic composition with a botulinum neurotoxin
US20060182767A1 (en) * 2002-05-28 2006-08-17 Borodic Gary E High-potency botulinum toxin formulations
US20070134199A1 (en) * 2003-07-22 2007-06-14 Biotecon Therapeutics Gmbh Formulation for a protein pharmaceutical without added human serum albumin (HSA)
US7964199B1 (en) * 1999-06-07 2011-06-21 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition comprising a botulinum neurotoxin
US20120122128A1 (en) * 2008-03-14 2012-05-17 Ester Fernandez-Salas Immuno-based botulinum toxin serotype a activity assays
US20140234857A1 (en) * 2011-09-29 2014-08-21 Cellsnap, Llc Compositions and methods for toxigenicity testing
US20160202245A1 (en) * 2013-06-28 2016-07-14 Merz Pharma Gmbh & Co. Kgaa Means and Methods for the determination of the biological activity of Neurotoxin polypeptides in cells
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964199B1 (en) * 1999-06-07 2011-06-21 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition comprising a botulinum neurotoxin
US20060182767A1 (en) * 2002-05-28 2006-08-17 Borodic Gary E High-potency botulinum toxin formulations
US20070134199A1 (en) * 2003-07-22 2007-06-14 Biotecon Therapeutics Gmbh Formulation for a protein pharmaceutical without added human serum albumin (HSA)
US20060018931A1 (en) * 2004-07-26 2006-01-26 Taylor Harold V Therapeutic composition with a botulinum neurotoxin
US20120122128A1 (en) * 2008-03-14 2012-05-17 Ester Fernandez-Salas Immuno-based botulinum toxin serotype a activity assays
US20140234857A1 (en) * 2011-09-29 2014-08-21 Cellsnap, Llc Compositions and methods for toxigenicity testing
US20160202245A1 (en) * 2013-06-28 2016-07-14 Merz Pharma Gmbh & Co. Kgaa Means and Methods for the determination of the biological activity of Neurotoxin polypeptides in cells
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186016A1 (zh) * 2022-04-01 2023-10-05 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物、制备方法及其应用

Also Published As

Publication number Publication date
EP4161562A1 (en) 2023-04-12
EP4467202A2 (en) 2024-11-27
KR20230020961A (ko) 2023-02-13
US20260144733A1 (en) 2026-05-28
JP2023529095A (ja) 2023-07-07
MX2022014564A (es) 2022-12-15
EP4161562B1 (en) 2024-11-20
WO2021245223A1 (en) 2021-12-09
EP4467202A3 (en) 2025-02-19
TW202214211A (zh) 2022-04-16
CA3177835A1 (en) 2021-12-09
AU2021286196A1 (en) 2022-12-01
ES3013130T3 (en) 2025-04-11
JP2026077675A (ja) 2026-05-13
US12599550B2 (en) 2026-04-14
IL298399A (en) 2023-01-01
US20230329996A1 (en) 2023-10-19
BR112022023413A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US12144847B2 (en) Non-protein clostridial toxin compositions
ES2880281T3 (es) Nanoemulsiones de botulinum
US12599550B2 (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
CN117279654A (zh) 用于治疗颈肌张力障碍的方法
JP2011157331A (ja) 高用量投与が可能なボツリヌス毒素製剤
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
TW202435908A (zh) 組成物及應用其之注射裝置
US20240207303A1 (en) mNA-based Delivery of Botulinum Toxin
KR20250113350A (ko) 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법
KR20240032688A (ko) 내성 발현이 감소된 보툴리눔 독소 제제 및 이와 관련된 방법
AU2023400493A1 (en) High concentration botulinum toxin treatment for neck rejuvenation
HK40054617A (en) Clostridial toxin-hyaluronic acid compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085901

Country of ref document: HK